{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:16:13Z","timestamp":1793301373114,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.ophtha.2009.04.016","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T10:46:14Z","timestamp":1248950774000},"page":"1630-1637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["GS-101 Antisense Oligonucleotide Eye Drops Inhibit Corneal Neovascularization"],"prefix":"10.1016","volume":"116","clinical-trial-number":[{"clinical-trial-number":"2004-005015-29","registry":"10.18810\/euctr"}],"author":[{"given":"Claus","family":"Cursiefen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert K.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich E.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Borderie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Geudelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Descohand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Steuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2009.04.016_bib1","series-title":"Cornea and External Eye Disease","first-page":"83","article-title":"New aspects of angiogenesis in the cornea","author":"Cursiefen","year":"2006"},{"key":"10.1016\/j.ophtha.2009.04.016_bib2","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":"Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2009.04.016_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2009.04.016_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00003226-199809000-00002","article-title":"Changing indications for penetrating keratoplasty: histopathology of 1,250 corneal buttons","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2009.04.016_bib6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.tp.0000285489.91595.13","article-title":"The immunobiology of corneal transplantation","volume":"84","author":"Williams","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.ophtha.2009.04.016_bib7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","article-title":"Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies","volume":"101","author":"Maguire","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.04.016_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.survophthal.2007.04.008","article-title":"Corneal graft rejection","volume":"52","author":"Panda","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib9","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.transproceed.2007.08.020","article-title":"Epidemiology and risk factors for corneal graft rejection","volume":"39","author":"Sellami","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ophtha.2009.04.016_bib10","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.04.016_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib12","unstructured":"Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative VEGF-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol. Epub ahead of print [Feb 17, 2009]."},{"key":"10.1016\/j.ophtha.2009.04.016_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.tp.0000191291.71003.1b","article-title":"An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty","volume":"81","author":"Birnbaum","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.ophtha.2009.04.016_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajo.2007.03.028","article-title":"Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty","volume":"144","author":"Nguyen","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s004170100313","article-title":"Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty","volume":"239","author":"Cursiefen","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.ophtha.2006.05.022","article-title":"Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes","volume":"113","author":"Price","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.04.016_bib17","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.04.016_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2009.04.016_bib19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.04.016_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.04.016_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/eye.2008.86","article-title":"The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration","volume":"22","author":"Dadgostar","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2009.04.016_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye [in German]","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ophtha.2009.04.016_bib23","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization [online report]","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.04.016_bib24","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":"Safety profile of topical VEGF-neutralization at the cornea","volume":"50","author":"Bock","year":"2009","journal-title":"nvest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.04.016_bib25","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1167\/iovs.05-0105","article-title":"Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis","volume":"46","author":"Andrieu-Soler","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.04.016_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.108.147496","article-title":"Potent in vivo anti-angiogenic effects of GS-101, (5\u2032-TATCCGGAGGGCTCGCCATGCTGCT-3\u2032), an antisense oligonucleotide preventing the expression of Insulin Receptor Substrate-1","volume":"329","author":"Al-Mahmood","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ophtha.2009.04.016_bib27","doi-asserted-by":"crossref","first-page":"31964","DOI":"10.1074\/jbc.M303314200","article-title":"Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis","volume":"278","author":"Jiang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ophtha.2009.04.016_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","article-title":"Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts","volume":"87","author":"Bock","year":"2008","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2009.04.016_bib29","first-page":"2291","article-title":"Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation","volume":"118","author":"Garcia","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ophtha.2009.04.016_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642009003698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642009003698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:57:41Z","timestamp":1758981461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642009003698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0161642009003698"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.016","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GS-101 Antisense Oligonucleotide Eye Drops Inhibit Corneal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}